Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.

Authors

Chun Wang
Zhaomei Mu
Zhong Ye
Zhenchao Zhang
Maysa M Abu-Khalaf
Daniel P Silver
Juan P Palazzo
Geetha Jagannathan
Frederick M Fellin
Saveri Bhattacharya
Rebecca J Jaslow
Theodore N Tsangaris
Adam Berger
Manish Neupane
Terrence P Cescon, Department of Hematology and Oncology, Reading Hospital - Tower Health, West Reading, PAFollow
AnaMaria Lopez
Kaelan Yao

Document Type

Article

Publication Date

6-1-2020

Abstract

PURPOSE: Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2

METHODS: cHER2 status was determined in 105 advanced-stage patients with tHER2

RESULTS: Compared to the patients with low-risk cHER2 (cHER2

CONCLUSION: In advanced-stage breast cancer patients with tHER2

Publication Title

Breast cancer research and treatment

Volume

181

Issue

3

First Page

679

Last Page

689

Recommended Citation

Wang, C., Mu, Z., Ye, Z., Zhang, Z., Abu-Khalaf, M., Silver, D., Palazzo, J., Jagannathan, G., Fellin, F., Bhattacharya, S., Jaslow, R., Tsangaris, T., Berger, A., Neupane, M., Cescon, T., Lopez, A., & Yao, K. (2020). Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.. Breast cancer research and treatment, 181 (3), 679-689. https://doi.org/https://doi.org/10.1007/s10549-020-05662-x